No. 349-Substance Use in Pregnancy

Journal of Obstetrics and Gynaecology Canada

Volumn 39, Issue 10, 2017, Pages 922-937.e2

  Ordean, Alice ^a   Wong, Suzanne ^a   Graves, Lisa ^a  

^a NONE   (Canada)

Author keywords

neonatal abstinence syndrome; Pregnancy; substance use; substance related disorders

Indexed keywords

BUPRENORPHINE; CANNABIS; METHADONE; OPIATE;

ARTICLE; BREAST FEEDING; CHRONIC PAIN; COMORBIDITY; DETOXIFICATION; DRUG DEPENDENCE; DRUG EFFICACY; DRUG FORMULATION; ELECTRONIC CIGARETTE; EVIDENCE BASED MEDICINE; HEALTH CARE ACCESS; HEALTH CARE COST; HEALTH CARE PERSONNEL; HUMAN; LACTATION; MATERNAL CARE; NEWBORN MORBIDITY; NEWBORN MORTALITY; PATIENT COUNSELING; PRACTICE GUIDELINE; PREGNANCY; PROFESSIONAL DEVELOPMENT; PROFESSIONAL KNOWLEDGE; PUERPERIUM; RISK ASSESSMENT; SCREENING TEST; SMOKING CESSATION; FEMALE; PREGNANCY COMPLICATION;

FEMALE; HUMANS; PREGNANCY; PREGNANCY COMPLICATIONS; SUBSTANCE-RELATED DISORDERS;

EID: 85029548308     PISSN: 17012163     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jogc.2017.04.028     Document Type: Article

References (158)

1. Public Health Agency of Canada, What mothers say: the Canadian maternity experiences survey. 2009, Public Health Agency of Canada, Ottawa.
2. Ries, R.K., The ASAM principles of addiction medicine. ed 5., 2014, Wolters Kluwer Health, Philadelphia, PA.
3. Lefebvre, L.G., Ordean, A., Midmer, D., et al. Physicians' knowledge of alcohol, tobacco and folic acid in pregnancy. Subst Abus 28 (2007), 3–9.
4. Leversha, A.M., Marks, R.E., Alcohol and pregnancy: doctors' attitudes, knowledge and clinical practice. N Z Med J 108 (1995), 428–430.
5. Gehshan, S., Missed opportunities for intervening in the lives of pregnant women addicted to alcohol or other drugs. J Am Med Womens Assoc 50 (1995), 160–163.
6. Nevin, A.C., Parshuram, C., Nulman, I., et al. A survey of physicians knowledge regarding awareness of maternal alcohol use and the diagnosis of FAS. BMC Fam Pract, 3, 2002, 2.
7. Public Health Agency of Canada, Knowledge and attitudes of health professionals about fetal alcohol syndrome: results of a national survey. 2005, Public Health Agency of Canada, Ottawa.
8. American Psychiatric Association, Diagnostic and statistical manual of mental disorders. ed 5., 2013, American Psychiatric Association, Arlington, VA.
9. Washington State Department of Health, Substance use disorders during pregnancy: guidelines for screening and management. 2016, Washington State Department of Health, Olympia, WA.
10. Hinderliter, S.A., Zelenak, J.P., A simple method to identify alcohol and other drug use in pregnant adults in a prenatal care setting. J Perinatol 13 (1993), 93–102.
11. Chang, G., Wilkins-Haug, L., Berman, S., et al. Alcohol use and pregnancy: improving identification. Obstet Gynecol 91 (1998), 892–898.
12. Carroll, J.C., Reid, A.J., Biringer, A., et al. Effectiveness of the Antenatal Psychosocial Health Assessment (ALPHA) form in detecting psychosocial concerns: a randomized controlled trial. CMAJ 173 (2005), 253–259.
13. Reid, A.J., Biringer, A., Carroll, J.D., et al. Using the ALPHA form in practice to assess antenatal psychosocial health. Antenatal Psychosocial Health Assessment. CMAJ 159 (1998), 677–684.
14. Washington State Department of Health, Guidelines for testing and reporting drug exposed newborns in Washington state. 2015, Washington State Department of Health, Olympia, WA.
15. Ostrea, E.M. Jr., Knapp, D.K., Tannenbaum, L., et al. Estimates of illicit drug use during pregnancy by maternal interview, hair analysis, and meconium analysis. J Pediatr 138 (2001), 344–348.
16. Callahan, C.M., Grant, T.M., Phipps, P., et al. Measurement of gestational cocaine exposure: sensitivity of infants' hair, meconium, and urine. J Pediatr 120 (1992), 763–768.
17. Vinner, E., Vignau, J., Thibault, D., et al. Neonatal hair analysis contribution to establishing a gestational drug exposure profile and predicting a withdrawal syndrome. Ther Drug Monit 25 (2003), 421–432.
18. Gourlay, D., Heit, H., Caplan, Y., Urine drug testing in primary care: dispelling the myths and designing strategies. 2002, California Academy of Family Physicans, San Francisco, CA.
19. Christmas, J.T., Knisely, J.S., Dawson, K.S., et al. Comparison of questionnaire screening and urine toxicology for detection of pregnancy complicated by substance use. Obstet Gynecol 80 (1992), 750–754.
20. Kwong, T.C., Shearer, D., Detection of drug use during pregnancy. Obstet Gynecol Clin North Am 25 (1998), 43–64.
21. Gehringer, K., Informed consent: hospitals must obtain informed consent prior to drug testing pregnant patients. J Law Med Ethics 31 (2003), 455–457.
22. Mikhail, B.I., Perceived impediments to prenatal care among low-income women. West J Nurs Res 21 (1999), 335–350 discussion 51–5.
23. Milligan, R., Wingrove, B.K., Richards, L., et al. Perceptions about prenatal care: views of urban vulnerable groups. BMC Public Health, 2, 2002, 25.
24. Currie, J.C., Best practices treatment and rehabilitation for women with substance use problems. 2001, Health Canada, Ottawa.
25. Roberts, G., Nanson, J., Best practices: fetal alcohol syndrome/fetal alcohol effects and the effects of other substance use during pregnancy. 2001, Health Canada, Ottawa.
26. Lee, M.I., Stryker, J.C., Sokol, R.J., Perinatal care for narcotic-dependent gravidas. Perinatol Neonatol 9 (1985), 35–40.
27. Chang, G., Carroll, K.M., Behr, H.M., et al. Improving treatment outcome in pregnant opiate-dependent women. J Subst Abuse Treat 9 (1992), 327–330.
28. Ellwood, D.A., Sutherland, P., Kent, C., et al. Maternal narcotic addiction: pregnancy outcome in patients managed by a specialized drug-dependency antenatal clinic. Aust N Z J Obstet Gynaecol 27 (1987), 92–98.
29. Kandall, S.R., Albin, S., Gartner, L.M., et al. The narcotic-dependent mother: fetal and neonatal consequences. Early Hum Dev 1 (1977), 159–169.
30. Burkett, G., Gomez-Marin, O., Yasin, S.Y., et al. Prenatal care in cocaine-exposed pregnancies. Obstet Gynecol 92 (1998), 193–200.
31. Suffet, F., Brotman, R., A comprehensive care program for pregnant addicts: obstetrical, neonatal, and child development outcomes. Int J Addict 19 (1984), 199–219.
32. Jansson, L.M., Svikis, D., Lee, J., et al. Pregnancy and addiction. A comprehensive care model. J Subst Abuse Treat 13 (1996), 321–329.
33. Sweeney, P.J., Schwartz, R.M., Mattis, N.G., et al. The effect of integrating substance abuse treatment with prenatal care on birth outcome. J Perinatol 20 (2000), 219–224.
34. Reece, E.A., Leguizamon, G., Silva, J., et al. Intensive interventional maternity care reduces infant morbidity and hospital costs. J Matern Fetal Neonatal Med 11 (2002), 204–210.
35. McLaughlin, F.J., Altemeier, W.A., Christensen, M.J., et al. Randomized trial of comprehensive prenatal care for low-income women: effect on infant birth weight. Pediatrics 89 (1992), 128–132.
36. Scholl, T.O., Hediger, M.L., Belsky, D.H., Prenatal care and maternal health during adolescent pregnancy: a review and meta-analysis. J Adolesc Health 15 (1994), 444–456.
37. Brands, B., Kahan, M., Selby, P., et al. Management of alcohol, tobacco and other drug problems: a physician's manual. 2000, Centre for Addiction and Mental Health, Toronto.
38. Wong, T., Lee, S.S., Hepatitis C: a review for primary care physicians. CMAJ 174 (2006), 649–659.
39. Vertical transmission of the hepatitis C virus: current knowledge and issues. Paediatr Child Health 13 (2008), 529–541.
40. Substance Abuse and Mental Health Services Administration, The NSDUH report: sexually transmitted diseases and substance use. 2007, Substance Abuse and Mental Health Services Administration, Rockville, MD.
41. Cavanaugh, C.E., Hedden, S.L., Latimer, W.W., Sexually transmitted infections among pregnant heroin- or cocaine-addicted women in treatment: the significance of psychiatric co-morbidity and sex trade. Int J STD AIDS 21 (2010), 141–142.
42. Bolnick, J.M., Rayburn, W.F., Substance use disorders in women: special considerations during pregnancy. Obstet Gynecol Clin North Am 30 (2003), 545–558 vii.
43. Messer, K., Clark, K.A., Martin, S.L., Characteristics associated with pregnant women's utilization of substance abuse treatment services. Am J Drug Alcohol Abuse 22 (1996), 403–422.
44. Martin, S.L., Beaumont, J.L., Kupper, L.L., Substance use before and during pregnancy: links to intimate partner violence. Am J Drug Alcohol Abuse 29 (2003), 599–617.
45. Johnson, H., Measuring violence against women: statistical trends. 2006, Statistics Canada, Ottawa.
46. Tuten, M., Jones, H.E., A partner's drug-using status impacts women's drug treatment outcome. Drug Alcohol Depend 70 (2003), 327–330.
47. Kissin, W.B., Svikis, D.S., Morgan, G.D., et al. Characterizing pregnant drug-dependent women in treatment and their children. J Subst Abuse Treat 21 (2001), 27–34.
48. Kissin, W.B., Svikis, D.S., Moylan, P., et al. Identifying pregnant women at risk for early attrition from substance abuse treatment. J Subst Abuse Treat 27 (2004), 31–38.
49. Tough, S.C., Siever, J.E., Johnston, D.W., Retaining women in a prenatal care randomized controlled trial in Canada: implications for program planning. BMC Public Health, 7, 2007, 148.
50. Ontario Ministry of Children and Youth Services, Reporting child abuse and neglect: it's your duty. 2010, Ontario Ministry of Children and Youth Services, Toronto.
51. Schempf, A.H., Strobino, D.M., Illicit drug use and adverse birth outcomes: is it drugs or context?. J Urban Health 85 (2008), 858–873.
52. Bailey, B.A., Daugherty, R.A., Intimate partner violence during pregnancy: incidence and associated health behaviors in a rural population. Matern Child Health J 11 (2007), 495–503.
53. Liston, R., Sawchuck, D., Young, D., et al. Fetal health surveillance: antepartum and intrapartum consensus guideline. J Obstet Gynaecol Can 29 (2007), S3–S56.
54. Chang, G., Goetz, M.A., Wilkins-Haug, L., et al. A brief intervention for prenatal alcohol use: an in-depth look. J Subst Abuse Treat 18 (2000), 365–369.
55. Project Choices Intervention Research Group, Reducing the risk of alcohol-exposed pregnancies: a study of a motivational intervention in community settings. Pediatrics 111 (2003), 1131–1135.
56. Davis, M.M., Brown, B.S., Glendinning, S.T., Neonatal effects of heroin addiction and methadone-treated pregnancies. Preliminary report on 70 live births. Proc Natl Conf Methadone Treat 2 (1973), 1153–1164.
57. Harper, R.G., Solish, G.I., Sang, E., et al. The effect of a methadone treatment program upon pregnant addicts and their infants. Proc Natl Conf Methadone Treat 2 (1973), 1133–1137.
58. Carroll, K.M., Chang, G., Behr, H., et al. Improving treatment outcome in pregnant, methadone-maintained women: results from a randomized clinical trial. Am J Addict 4 (1995), 56–59.
59. Dutra, L., Stathopoulou, G., Basden, S.L., et al. A meta-analytic review of psychosocial interventions for substance use disorders. Am J Psychiatry 165 (2008), 179–187.
60. Nordstrom, B.R., Levin, F.R., Treatment of cannabis use disorders: a review of the literature. Am J Addict 16 (2007), 331–342.
61. World Health Organization, Guidelines for the identification and management of substance use and substance disorders in pregnancy. 2014, World Health Organization, Geneva.
62. Milligan, K., Niccols, A., Sword, W., et al. Maternal substance use and integrated treatment programs for women with substance abuse issues and their children: a meta-analysis. Subst Abuse Treat Prev Policy, 5, 2010, 21.
63. Finnegan, L., Substance abuse in Canada. Licit and illicit drug use during pregnancy: maternal, neonatal and early childhood consequences. 2013, Candian Centre on Substance Abuse, Ottawa.
64. Ordean, A., Kahan, M., Graves, L., et al. Integrated care for pregnant women on methadone maintenance treatment: Canadian primary care cohort study. Can Fam Physician 59 (2013), e462–e469.
65. Ordean, A., Kahan, M., Graves, L., et al. Obstetrical and neonatal outcomes of methadone-maintained pregnant women: a Canadian multisite cohort study. J Obstet Gynaecol Can 37 (2015), 252–257.
66. College of Physians and Surgeons of Novia Scotia, Methadone maintenance treatment: program standards and clinical guidelines. ed 4., 2011, College of Physians and Surgeons of Novia Scotia, Toronto.
67. Rore, C., Brace, V., Danielian, P., et al. Smoking cessation in pregnancy. Expert Opin Drug Saf 7 (2008), 727–737.
68. Crawford, J.T., Tolosa, J.E., Goldenberg, R.L., Smoking cessation in pregnancy: why, how, and what next. Clin Obstet Gynecol 51 (2008), 419–435.
69. Coleman T, Chamberlain C, Davey MA, et al. Pharmacological interventions for promoting smoking cessation during pregnancy. Cochrane Database of Systematic Reviews 2015, Issue 12. Art. No.: CD010078. DOI: 10.1002/14651858.CD010078.pub2.
70. McBride, C.M., Baucom, D.H., Peterson, B.L., et al. Prenatal and postpartum smoking abstinence a partner-assisted approach. Am J Prev Med 27 (2004), 232–238.
71. Rigotti, N.A., Park, E.R., Regan, S., et al. Efficacy of telephone counseling for pregnant smokers: a randomized controlled trial. Obstet Gynecol 108 (2006), 83–92.
72. Melvin, C.L., Dolan-Mullen, P., Windsor, R.A., et al. Recommended cessation counselling for pregnant women who smoke: a review of the evidence. Tob Control 9:Suppl 3 (2000), III80–III84.
73. Kapur, B., Hackman, R., Selby, P., et al. Randomized, double-blind, placebo-controlled trial of nicotine replacement therapy in pregnancy. Curr Ther Res Clin Exp 62 (2001), 274–278.
74. Pollak, K.I., Oncken, C.A., Lipkus, I.M., et al. Nicotine replacement and behavioral therapy for smoking cessation in pregnancy. Am J Prev Med 33 (2007), 297–305.
75. Fajemirokun-Odudeyi, O., Sinha, C., Tutty, S., et al. Pregnancy outcome in women who use opiates. Eur J Obstet Gynecol Reprod Biol 126 (2006), 170–175.
76. Hajek P, Stead LF, West R, et al. Relapse prevention interventions for smoking cessation. Cochrane Database of Systematic Reviews 2013, Issue 8. Art. No.: CD003999. DOI: 10.1002/14651858.CD003999.pub4.
77. Oncken, C., Dornelas, E., Greene, J., et al. Nicotine gum for pregnant smokers: a randomized controlled trial. Obstet Gynecol 112 (2008), 859–867.
78. Dwyer, J.B., Broide, R.S., Leslie, F.M., Nicotine and brain development. Birth Defects Res C Embryo Today 84 (2008), 30–44.
79. Slotkin, T.A., If nicotine is a developmental neurotoxicant in animal studies, dare we recommend nicotine replacement therapy in pregnant women and adolescents?. Neurotoxicol Teratol 30 (2008), 1–19.
80. Gaither, K.H., Brunner Huber, L.R., Thompson, M.E., et al. Does the use of nicotine replacement therapy during pregnancy affect pregnancy outcomes?. Matern Child Health J 13 (2009), 497–504.
81. Morales-Suarez-Varela, M.M., Bille, C., Christensen, K., et al. Smoking habits, nicotine use, and congenital malformations. Obstet Gynecol 107 (2006), 51–57.
82. Pauly, J.R., Slotkin, T.A., Maternal tobacco smoking, nicotine replacement and neurobehavioural development. Acta Paediatr 97 (2008), 1331–1337.
83. Coleman, T., Recommendations for the use of pharmacological smoking cessation strategies in pregnant women. CNS Drugs 21 (2007), 983–993.
84. Chun-Fai-Chan, B., Koren, G., Fayez, I., et al. Pregnancy outcome of women exposed to bupropion during pregnancy: a prospective comparative study. Am J Obstet Gynecol 192 (2005), 932–936.
85. Chan, B., Einarson, A., Koren, G., Effectiveness of bupropion for smoking cessation during pregnancy. J Addict Dis 24 (2005), 19–23.
86. Luty, J., Nikolaou, V., Bearn, J., Is opiate detoxification unsafe in pregnancy?. J Subst Abuse Treat 24 (2003), 363–367.
87. Kashiwagi, M., Arlettaz, R., Lauper, U., et al. Methadone maintenance program in a Swiss perinatal center: (I): management and outcome of 89 pregnancies. Acta Obstet Gynecol Scand 84 (2005), 140–144.
88. Dashe, J.S., Jackson, G.L., Olscher, D.A., et al. Opioid detoxification in pregnancy. Obstet Gynecol 92 (1998), 854–858.
89. Maas, U., Kattner, E., Weingart-Jesse, B., et al. Infrequent neonatal opiate withdrawal following maternal methadone detoxification during pregnancy. J Perinat Med 18 (1990), 111–118.
90. Allen, M.H., Detoxification considerations in the medical management of substance abuse in pregnancy. Bull N Y Acad Med 67 (1991), 270–276.
91. Blinick, G., Inturrisi, C.E., Jerez, E., et al. Methadone assays in pregnant women and progeny. Am J Obstet Gynecol 121 (1975), 617–621.
92. Stern, R., The pregnant addict. A study of 66 case histories, 1950-1959. Am J Obstet Gynecol 94 (1966), 253–257.
93. Wilson, G.S., Desmond, M.M., Wait, R.B., Follow-up of methadone-treated and untreated narcotic-dependent women and their infants: health, developmental, and social implications. J Pediatr 98 (1981), 716–722.
94. Jones, H.E., O'Grady, K.E., Malfi, D., et al. Methadone maintenance vs. methadone taper during pregnancy: maternal and neonatal outcomes. Am J Addict 17 (2008), 372–386.
95. Hagopian, G.S., Wolfe, H.M., Sokol, R.J., et al. Neonatal outcome following methadone exposure in utero. J Matern Fetal Med 5 (1996), 348–354.
96. Kandall, S.R., Albin, S., Lowinson, J., et al. Differential effects of maternal heroin and methadone use on birthweight. Pediatrics 58 (1976), 681–685.
97. Hulse, G.K., Milne, E., English, D.R., et al. The relationship between maternal use of heroin and methadone and infant birth weight. Addiction 92 (1997), 1571–1579.
98. Giles, W., Patterson, T., Sanders, F., et al. Outpatient methadone programme for pregnant heroin using women. Aust N Z J Obstet Gynaecol 29 (1989), 225–229.
99. Edelin, K.C., Gurganious, L., Golar, K., et al. Methadone maintenance in pregnancy: consequences to care and outcome. Obstet Gynecol 71 (1988), 399–404.
100. Zelson, C., Lee, S.J., Casalino, M., Neonatal narcotic addiction. Comparative effects of maternal intake of heroin and methadone. N Engl J Med 289 (1973), 1216–1220.
101. Rahbar, F., Observations on methadone withdrawal in 16 neonates. Clin Pediatr (Phila) 14 (1975), 369–371.
102. Malpas, T.J., Darlow, B.A., Lennox, R., et al. Maternal methadone dosage and neonatal withdrawal. Aust N Z J Obstet Gynaecol 35 (1995), 175–177.
103. Brown, H.L., Britton, K.A., Mahaffey, D., et al. Methadone maintenance in pregnancy: a reappraisal. Am J Obstet Gynecol 179 (1998), 459–463.
104. Arlettaz, R., Kashiwagi, M., Das-Kundu, S., et al. Methadone maintenance program in pregnancy in a Swiss perinatal center (II): neonatal outcome and social resources. Acta Obstet Gynecol Scand 84 (2005), 145–150.
105. Hunt, R.W., Tzioumi, D., Collins, E., et al. Adverse neurodevelopmental outcome of infants exposed to opiate in-utero. Early Hum Dev 84 (2008), 29–35.
106. Vance, J.C., Chant, D.C., Tudehope, D.I., et al. Infants born to narcotic dependent mothers: physical growth patterns in the first 12 months of life. J Paediatr Child Health 33 (1997), 504–508.
107. Srivastava, A., Kahan, M., Buprenorphine: a potential new treatment option for opioid dependence. CMAJ, 174, 2006, 1835.
108. Johnson, R.E., Jones, H.E., Fischer, G., Use of buprenorphine in pregnancy: patient management and effects on the neonate. Drug Alcohol Depend 70 (2003), S87–S101.
109. Lacroix, I., Berrebi, A., Chaumerliac, C., et al. Buprenorphine in pregnant opioid-dependent women: first results of a prospective study. Addiction 99 (2004), 209–214.
110. Lejeune, C., Simmat-Durand, L., Gourarier, L., et al. Prospective multicenter observational study of 260 infants born to 259 opiate-dependent mothers on methadone or high-dose buprenophine substitution. Drug Alcohol Depend 82 (2006), 250–257.
111. Jones, H.E., Johnson, R.E., Jasinski, D.R., et al. Buprenorphine versus methadone in the treatment of pregnant opioid-dependent patients: effects on the neonatal abstinence syndrome. Drug Alcohol Depend 79 (2005), 1–10.
112. Schindler, S.D., Eder, H., Ortner, R., et al. Neonatal outcome following buprenorphine maintenance during conception and throughout pregnancy. Addiction 98 (2003), 103–110.
113. Jones, H.E., Kaltenbach, K., Heil, S.H., et al. Neonatal abstinence syndrome after methadone or buprenorphine exposure. N Engl J Med 363 (2010), 2320–2331.
114. Minozzi S, Amato L, Bellisario C, et al. Maintenance agonist treatments for opiate-dependent pregnant women. Cochrane Database of Systematic Reviews 2013, Issue 12. Art. No.: CD006318. DOI: 10.1002/14651858.CD006318.pub3.
115. Brogly, S.B., Saia, K.A., Walley, A.Y., et al. Prenatal buprenorphine versus methadone exposure and neonatal outcomes: systematic review and meta-analysis. Am J Epidemiol 180 (2014), 673–686.
116. Lifshitz, M., Gavrilov, V., Galil, A., et al. A four year survey of neonatal narcotic withdrawal: evaluation and treatment. Isr Med Assoc J 3 (2001), 17–20.
117. McCarthy, J.J., Leamon, M.H., Parr, M.S., et al. High-dose methadone maintenance in pregnancy: maternal and neonatal outcomes. Am J Obstet Gynecol 193 (2005), 606–610.
118. O'Connor, A., Alto, W., Musgrave, K., et al. Observational study of buprenorphine treatment of opioid-dependent pregnant women in a family medicine residency: reports on maternal and infant outcomes. J Am Board Fam Med 24 (2011), 194–201.
119. Cleary, B.J., Donnelly, J., Strawbridge, J., et al. Methadone dose and neonatal abstinence syndrome-systematic review and meta-analysis. Addiction 105 (2010), 2071–2084.
120. Debelak, K., Morrone, W.R., O'Grady, K.E., et al. Buprenorphine + naloxone in the treatment of opioid dependence during pregnancy-initial patient care and outcome data. Am J Addict 22 (2013), 252–254.
121. Wiegand, S.L., Stringer, E.M., Stuebe, A.M., et al. Buprenorphine and naloxone compared with methadone treatment in pregnancy. Obstet Gynecol 125 (2015), 363–368.
122. Dooley, J., Gerber-Finn, L., Antone, I., et al. Buprenorphine-naloxone use in pregnancy for treatment of opioid dependence: restrospective cohort study of 30 patients. Can Fam Physician 62 (2016), e194–e3200.
123. National Opioid Use Guideline Group, Canadian guideline for safe and effective use of opioids for chronic non-cancer pain. 2010, McMaster University, Hamilton, ON.
124. Hadi, I., da Silva, O., Natale, R., et al. Opioids in the parturient with chronic nonmalignant pain: a retrospective review. J Opioid Manag 2 (2006), 31–34.
125. Sharpe, C., Kuschel, C., Outcomes of infants born to mothers receiving methadone for pain management in pregnancy. Arch Dis Child Fetal Neonatal Ed 89 (2004), F33–F36.
126. Jansson, L.M., Velez, M., Harrow, C., The opioid-exposed newborn: assessment and pharmacologic management. J Opioid Manag 5 (2009), 47–55.
127. Marcellus, L., Care of substance-exposed infants: the current state of practice in Canadian hospitals. J Perinat Neonatal Nurs 16 (2002), 51–68.
128. Velez, M., Jansson, L.M., The opioid dependent mother and newborn dyad: non-pharmacologic care. J Addict Med 2 (2008), 113–120.
129. Osborn DA, Jeffery HE, Cole MJ. Opiate treatment for opiate withdrawal in newborn infants. Cochrane Database of Systematic Reviews 2010, Issue 10. Art. No.: CD002059. DOI:.
130. Abrahams, R.R., Kelly, S.A., Payne, S., et al. Rooming-in compared with standard care for newborns of mothers using methadone or heroin. Can Fam Physician 53 (2007), 1722–1730.
131. Porath-Waller, A.J., Clearing the smoke on cannabis: maternal cannabis use durin gpregnancy - an update. 2015, Canadian Centre on Substance Abuse, Ottawa.
132. American College of Obstetricians and Gynecologists Committee on Obstetric Practice, Committee opinion No. 637: marijuana use during pregnancy and lactation. Obstet Gynecol 126 (2015), 234–238.
133. Cassidy, B., Cyna, A.M., Challenges that opioid-dependent women present to the obstetric anaesthetist. Anaesth Intensive Care 32 (2004), 494–501.
134. May, J.A., White, H.C., Leonard-White, A., et al. The patient recovering from alcohol or drug addiction: special issues for the anesthesiologist. Anesth Analg 92 (2001), 1601–1608.
135. Mao, J., Opioid-induced abnormal pain sensitivity: implications in clinical opioid therapy. Pain 100 (2002), 213–217.
136. Rapp, S.E., Ready, L.B., Nessly, M.L., et al. Acute pain management in patients with prior opioid consumption: a case-controlled retrospective review. Pain 61 (1995), 195–201.
137. Mehta, V., Langford, R.M., Acute pain management for opioid dependent patients. Anaesthesia 61 (2006), 269–276.
138. Meyer, M., Wagner, K., Benvenuto, A., et al. Intrapartum and postpartum analgesia for women maintained on methadone during pregnancy. Obstet Gynecol 110 (2007), 261–266.
139. Substance Abuse and Mental Health Services Administration, TIP 43: medication-assisted treatment for opioid addiction in opioid treatment programs. 2012, U.S. Department of Health and Human Services, Rockville, MD.
140. Perez-Reyes, M., Wall, M.E., Presence of delta9-tetrahydrocannabinol in human milk. N Engl J Med 307 (1982), 819–820.
141. Astley, S.J., Little, R.E., Maternal marijuana use during lactation and infant development at one year. Neurotoxicol Teratol 12 (1990), 161–168.
142. Chasnoff, I.J., Lewis, D.E., Squires, L., Cocaine intoxication in a breast-fed infant. Pediatrics 80 (1987), 836–838.
143. Steiner, E., Villen, T., Hallberg, M., et al. Amphetamine secretion in breast milk. Eur J Clin Pharmacol 27 (1984), 123–124.
144. Chaney, N.E., Franke, J., Wadlington, W.B., Cocaine convulsions in a breast-feeding baby. J Pediatr 112 (1988), 134–135.
145. Hopkinson, J.M., Schanler, R.J., Fraley, J.K., et al. Milk production by mothers of premature infants: influence of cigarette smoking. Pediatrics 90 (1992), 934–938.
146. Robieux, I., Koren, G., Vandenbergh, H., et al. Morphine excretion in breast milk and resultant exposure of a nursing infant. J Toxicol Clin Toxicol 28 (1990), 365–370.
147. Kreek, M.J., Schecter, A., Gutjahr, C.L., et al. Analyses of methadone and other drugs in maternal and neonatal body fluids: use in evaluation of symptoms in a neonate of mother maintained on methadone. Am J Drug Alcohol Abuse 1 (1974), 409–419.
148. Pond, S.M., Kreek, M.J., Tong, T.G., et al. Altered methadone pharmacokinetics in methadone-maintained pregnant women. J Pharmacol Exp Ther 233 (1985), 1–6.
149. Geraghty, B., Graham, E.A., Logan, B., et al. Methadone levels in breast milk. J Hum Lact 13 (1997), 227–230.
150. Johnson, R.E., Jones, H.E., Jasinski, D.R., et al. Buprenorphine treatment of pregnant opioid–dependent women: maternal and neonatal outcomes. Drug Alcohol Depend 63 (2001), 97–103.
151. Marquet, P., Chevrel, J., Lavignasse, P., et al. Buprenorphine withdrawal syndrome in a newborn. Clin Pharmacol Ther 62 (1997), 569–571.
152. McCarthy, J.J., Posey, B.L., Methadone levels in human milk. J Hum Lact 16 (2000), 115–120.
153. Pritham, U.A., Breastfeeding promotion for management of neonatal abstinence syndrome. J Obstet Gynecol Neonatal Nurs 42 (2013), 517–526.
154. Welle-Strand, G.K., Skurtveit, S., Jansson, L.M., et al. Breastfeeding reduces the need for withdrawal treatment in opioid-exposed infants. Acta Paediatr 102 (2013), 1060–1066.
155. O'Connor, A.B., Collett, A., Alto, W.A., et al. Breastfeeding rates and the relationship between breastfeeding and neonatal abstinence syndrome in women maintained on buprenorphine during pregnancy. J Midwifery Womens Health 58 (2013), 383–388.
156. Jansson, L.M., Spencer, N., McConnell, K., et al. Maternal buprenorphine maintenance and lactation. J Hum Lact 32 (2016), 675–681.
157. Madadi, P., Moretti, M., Djokanovic, N., et al. Guidelines for maternal codeine use during breastfeeding. Can Fam Physician 55 (2009), 1077–1078.
158. Madadi, P., Ross, C.J., Hayden, M.R., et al. Pharmacogenetics of neonatal opioid toxicity following maternal use of codeine during breastfeeding: a case-control study. Clin Pharmacol Ther 85 (2009), 31–35.